Medicamen Organics Limited — Important, 14-11-2024: Financial Result Updates

**Consolidated Financials:** Medicamen Organics has released its unaudited financial results for the half-year ended September 30, 2024.

**Revenue Growth:** Total revenue from operations reached ₹16.61 crore, reflecting a 19% year-over-year increase from ₹11.32 crore in the same period last year. Factors driving this growth include enhanced demand amid market expansion efforts.

**Profit and EPS:** The company reported a net profit of ₹15.11 crore, up from ₹13.63 crore in the previous year, translating to an Earnings Per Share (EPS) of ₹1.48, marginally lower than ₹1.99 from the previous half-year. Improved operational efficiencies and higher sales volumes contributed positively to profitability.

**Operational Costs:** Total expenses increased by 19% to ₹14.67 crore, attributed to rising material costs and employee benefits. Key areas of focus for cost control include streamlining operations to balance the impact of increased costs.

**Balance Sheet & Cash Flow Statement:** Total assets increased from ₹38.11 crore to ₹48.99 crore, bolstered by cash inflows from a recent IPO, which has strengthened cash reserves. Notably, the company reported a net cash outflow from operating activities of ₹8.71 crore, attributed to increased working capital requirements.

**Strategic Position and Outlook:** The company shows a robust strategic focus on expanding its international footprint, evidenced by plans to acquire a stake in Depot Pharmacy Yego Ltd. This move aligns with its long-term growth strategy amid ongoing sectoral challenges.

**Investor Insight:** Given the revenue growth and operational improvements, Medicamen Organics appears to be in a solid position. Considering both growth prospects and ongoing cost management initiatives, it presents a compelling case for investors looking for sustained performance in the sector.